Cleared Traditional

IVD TECHNOLOGIES ACHRAB TEST KIT (K091468) - FDA 510(k) Clearance

Class II Immunology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K091468 · Ivd Technologies · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2009
Decision
186d
Days
Class 2
Risk

K091468 is an FDA 510(k) clearance for the IVD TECHNOLOGIES ACHRAB TEST KIT. Classified as Autoantibodies, Acetylcholine Receptor, Acetylcholine Blocking And Non-blocking (product code NST), Class II - Special Controls.

Submitted by Ivd Technologies (East Stroudsburg, US). The FDA issued a Cleared decision on November 20, 2009 after a review of 186 days - an extended review cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Ivd Technologies devices

Submission Details

510(k) Number K091468 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 18, 2009
Decision Date November 20, 2009
Days to Decision 186 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
82d slower than avg
Panel avg: 104d · This submission: 186d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NST Autoantibodies, Acetylcholine Receptor, Acetylcholine Blocking And Non-blocking
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
Definition The Device Is An Immunoassay Indicated As An Aid In The Diagnosis Of Myasthenia Gravis, An Autoimmune Disease Characterized By Exercise-induced Muscle Weakness Temporarily Relieved By Cessation Of Exercise. Autoantibody, When Present In Serum, Interferes With The Binding Of Acetylcholine, A Neural Transmitter At The Junction Of Nerves With Muscles. Autoantibody Can Also Bind To Other Portions Of The Acetylcholine Receptor Without Interfering With Acetylcholine Binding. Presence Of Autoantibody Along With Clinical Signs And Symptoms Are Usually Highly Suggestive Of Myasthenia Gravis. Acetylcholine Receptor Autoantibody Can Also Occur In The Presence Of Autoantibodies To Other Body Substances.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.